Immunohistochemical assessment of a unique basal pattern of p53 expression in ulcerative-colitis-associated neoplasia using computer-assisted cytometry
- Shunsuke Kobayashi†1, 2,
- Takahiro Fujimori†1,
- Hiroyuki Mitomi1Email author,
- Shigeki Tomita1,
- Kazuhito Ichikawa1,
- Johji Imura3,
- Shigehiko Fujii4,
- Michihiro Itabashi5,
- Shingo Kameoka5 and
- Yoshinori Igarashi2
© Kobayashi et al.; licensee BioMed Central Ltd. 2014
Received: 31 March 2014
Accepted: 14 May 2014
Published: 29 May 2014
The basal pattern of p53 expression, defined as its immunoreactivity confined to the basal half of the glands, is associated with early neoplastic lesions in ulcerative colitis (UC). However, their clinical utility of this finding is limited by the use of “visual estimation” (approximate immunoreactivity on the basis of scanning the stained slide, without formal counting). This study was designed to analyze the basal pattern of p53 using computer-assisted cytometry and to identify the optimal cutoff value for discriminating between UC-associated early-stage neoplasia and regenerative atypia.
The specimens were obtained from eight UC patients undergoing colectomy and were classified according to the criteria by the Research Committee of Inflammatory Bowel Disease of the Ministry of Health and Welfare in Japan. Patients with classes UC-IIa (indefinite for dysplasia, probably regenerative), UC-IIb (indefinite for dysplasia, probably dysplastic), and UC-III (definitive dysplasia) were enrolled in the study. Based on the percentage of immunoreactive cells in the basal half of the crypt with visual estimation, basal positivity of p53 was classified into three categories: grade 1 (1 - 9%), grade 2 (10 - 19%), and grade 3 (≥20%). Next, crypts classified as grade 3 by visual estimation were analyzed by computer-assisted image analysis.
Using visual estimation, grade-3 p53 basal positivity was observed in 46.0% of UC-IIa crypts (128 of 278), 61.9% of UC-IIb crypts (39 of 63), and 94.2% of UC-III crypts (81 of 86). Using image analysis, the median p53 basal positivities were 30.3% in UC-IIa, 52.3% in UC-IIb, and 65.4% in UC-III (P ≤0.002). A receiver operating characteristics curve was generated to determine the method’s diagnostic utility in differentiating UC-IIa from UC-III. In this cohort, the sensitivity was 0.78; the specificity was 0.98; the negative predictive value was 87.4%; the positive predictive value was 95.5%, and the accuracy was 90.2% with a cutoff value for p53 basal positivity of 46.1%.
Our findings indicate that assessing p53 basal positivity by image analysis with an optimal threshold represents an alternative to visual estimation for the accurate diagnosis of UC-associated early-stage neoplasia.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3588120501252608
KeywordsUlcerative colitis p53 Immunohistochemistry Computer-assisted cytometry Dysplasia
There is an increasing incidence of ulcerative colitis (UC)-associated neoplasia among patients with long-standing and extensive disease [1, 2]. However, UC-associated early-stage neoplasia is not easily detected by endoscopy, because those lesions are sometimes missed among the inflamed epithelium . In addition, the histological diagnosis of early-stage neoplasia, which often has unremarkable cytological alterations , is difficult due to the recurrent and persistent inflammatory changes associated with UC. Other difficulties in early detection result from specific histological features of UC-associated early-stage neoplasia, which can involve only one part of the crypt or a few crypts in the inflamed epithelium . Consequently, it is difficult to distinguish UC-associated early-stage neoplasia from regenerative atypia in biopsy specimens stained with hematoxylin and eosin (H&E) . Moreover, there is a concerning degree of inter- and intra-observer variation in the diagnosis of UC-associated early-stage neoplasia and regenerative atypia among gastrointestinal pathologists .
Mutations in the p53 gene represent an early event in the development of UC-associated neoplasia [6–8]. Immunohistochemical analysis of the p53 protein is a useful method for detecting UC-associated early-stage neoplasia, since there is a concordance between p53 gene mutation and its expression [7–9]. Immunohistochemstry for p53 was positive in 11 - 75% of low-grade dysplasia and 45 - 83% of high-grade dysplasia but was negative in regenerative epithelium in UC [9–12]. Accordingly, Wong et al. reported intense p53 staining in 14% of low-grade dysplasia and 57% of high-grade dysplasia but not in regenerative epithelium with atypia in UC . They reported that restriction of p53 expression to the basal two-thirds of the crypt excluded a diagnosis of UC-associated high-grade dysplasia. Noffsinger et al. reported that p53 basal expression was associated with p53 mutation and represented an early neoplastic change in a subgroup of UC patients . Moreover, UC-associated early-stage neoplasia had a significantly higher proportion and a different pattern of p53 immunoreactivity than sporadic adenoma [11, 14]. The immunoreactivity in sporadic adenomas had a scattered or sporadic pattern of p53 expression , while UC-associated early-stage neoplasia exhibited a “bottom-up” pattern [7, 13]. However, the utility of these reports is limited by the “visual estimation” of basal pattern of p53 immunoreactivity, where the approximate immunoreactivity was determined by scanning the stained slide without formal counting . Recently, the emergence of digital pathology and software analysis of data has led to the development of a reliable and reproducible digital analytical technique for Ki-67 immunoreactivity [15, 16].
The aim of this study was to analyze the basal pattern of p53 immunoreactivity using computer-assisted cytometry and to identify the optimal cutoff value for basal positivity of p53 in order to discriminate between UC-associated early-stage neoplasia and regenerative atypia.
Patients and materials
Tissue samples were obtained from eight UC patients (five males and three females; mean/median age, 46.0/47.5 years, range, 21–67 years; mean/median duration of disease, 21.3/15.0 years, range 6–43 years) who underwent total colectomy for UC-associated neoplasia at Tokyo Women’s Medical University and Dokkyo Medical University School of Medicine between January 2010 and December 2011.
Colectomy specimens were fixed in 10% formalin and cut to a width of 5 mm and then embedded in paraffin, sectioned, and stained with H&E. The specimens were histologically evaluated by three experienced gastrointestinal pathologists (S.K., T.F., H.M.) and were classified according to the classification proposed by the Research Committee of Inflammatory Bowel Disease of the Ministry of Health and Welfare in Japan . Inter-observer variations were resolved by reevaluation and discussion to reach consensus. Patients classified as having UC-IIa (indefinite for dysplasia, probably regenerative), UC-IIb (indefinite for dysplasia, probably dysplastic), and UC-III (low or high-grade dysplasia) were enrolled in this study.
The Ethics Committee of Dokkyo Medical University School of Medicine approved all protocols, and informed consent for tissue procurement was obtained from all patients. Samples used in this study were surgically resected for treatment, not for research purposes. Participation in the present study did not increase medical disadvantage or risk to patients.
Immunohistochemistry for p53
Briefly, 4-μm-thick serial sections were placed on silane-coated slides, deparaffinized, rehydrated, and pretreated with 0.3% hydrogen peroxidase in methanol at room temperature to quench endogenous peroxidase activity. The sections were then placed in 0.01 M citrate buffer (pH 6.0) and treated by microwave heating (MI-77, Azumaya, Tokyo, Japan; 400 W, 95°C) to facilitate antigen retrieval. The sections were incubated with 1% bovine serum albumin in phosphate-buffered saline and then with a monoclonal anti-human p53 antibody (DO-7; 1:50 dilution; DAKO, Glostrub, Denmark). Immunohistochemical staining was performed with EnVisionTM + Kits (DAKO). Finally, the sections were incubated with 3,3′-diaminobenzidine and counterstained lightly with Carazzi’s hematoxylin.
Visual estimation of p53 expression
Neoplastic lesions in each p53-immunostained slide were confirmed using the corresponding H&E-stained specimens. We evaluated the unique basal pattern of p53 expression, which was characterized by p53 immunoreactivity in the basal half of the crypts, as described by Noffisinger et al. . In addition, the unique basal pattern of p53 expression was classified into three categories according to the percentage of immunoreactive cells in the basal half of the crypt as follows: grade 1 (1 - 9%); grade 2 (10 - 19%), and grade 3 (≥20%). Immunohistochemical images were imported into a PowerPoint presentation and evaluated by two independent researchers (T.F. and S.K.), who estimated the grade of p53 immunoreactivity based on their inspection of the images without using computer-assisted image analysis (‘visual estimation’). Inter-observer disagreements were resolved by reevaluation and discussion to a reach consensus.
Analysis of p53 expression using computer-assisted cytometry
Crypts classified as grade 3 by visual estimation were analyzed using the computer-assisted cytometry with WinROOF image-processing software (Mitani Corp., Tokyo, Japan). The glands subjected to image analysis were continuously visible from the bottom of the glands to the surface epithelium. The manual counting function of the image analysis was utilized, and p53-positive cells in the basal half of the crypts were counted under high-power magnification (at 400X) using a touch pen by introducing a liquid crystal touch panel. The values were expressed as the percentage of p53-positive cells relative to the total number of crypt cells in the basal half of the glands.
Continuous data were analyzed with the Mann–Whitney U-test using Stat Flex Version 6.0 (Artec Co. Ltd., Osaka, Japan). A P-value < 0.05 was considered statistically significant. A receiver operating characteristics (ROC) curve was generated with R Version 3.0.1 statistical software.
A total of 1,039 crypts (a total of 103 lesions) consisting of 626 UC-IIa crypts (total 40 lesions; Case #1, 13 lesions; Case #3, 1 lesion; Case #4, 1 lesion; Case #7, 12 lesions; Case #8, 13 lesions), 256 UC-IIb crypts (40 lesions; Case #1, 10 lesions; Case #2, 6 lesions; Case #3, 10 lesions; Case #4, 6 lesions; Case #5, 4 lesions; Case #6, 4 lesions), and 157 UC-III crypts (23 lesions; Case #1, 7 lesions; Case #2, 9 lesions; Case #3, 3 lesions; Case #5: 3 lesions; Case #6, 1 lesion) were examined by visual estimation.
Grade of p53 basal positivity in the crypts in UC-IIa, IIb, and III lesions
Grade of p53 basal positivity
(n = 278)
(n = 63)
(n = 86)
Frequency of UC-IIa, IIb, and III based on a new p53 basal positivity cutoff value
p53 basal positivity
(n = 128)
(n = 39)
(n = 81)
20.0 - 46.0
In the present study, we investigated the basal pattern of p53 immunoreactivity in UC-III (definite dysplasia) and UC-II (indefinite for dysplasia) crypts using computer-assisted cytometry and determined the optimal cutoff value for basal positivity of p53 for discriminating between the two categories. By visual estimation, Grade-3 p53 basal positivity was observed in 46.0% of UC-IIa crypts (indefinite for dysplasia, probably regenerative), 61.9% of UC-IIb crypts (indefinite for dysplasia, probably dysplastic), and 94.2% of UC-III crypts. Our data are consistent with the previously published hypothesis that the basal pattern of p53 expression is not a specific sign of dysplasia (UC-III); rather, this pattern was observed in 5 - 64% of regenerative mucosa and 13 - 33% of samples indefinite for dysplasia [7, 13].
There is significant discordance between visual estimation and digital image analysis for Ki-67 immunoreactivity . Thus, we performed computer-assisted cytometrical analysis using the WinRooF image-processing software, which we developed in our previous study on Ki-67 immunoreactivity , for grade-3 p53 basal positivity by visual estimation. We could exclude non-neoplastic (dysplastic) cells that occasionally display nonspecific positivity for p53, such as lymphocytes or histiocytes, using a touch pen by introducing a touch panel. Using this analysis, we identified that p53 basal positivity was significantly higher in UC-III crypts (median value, 65.4%) than in UC-IIb crypts (52.3%) or UC-IIa crypts (30.3%). However, the ROC curve indicated a low sensitivity (0.42) and negative predictive value (42.0%) in differentiating between UC-III and UC-IIb. Based on this result, we considered the possibility that some of the UC-IIb crypts might be included in the UC-III category. Indeed, 80% of UC-IIb crypts harbored p53 mutations .
Colectomy is often indicated in patients with a diagnosis of UC-III, whereas those with UC-IIa should undergo repeat surveillance colonoscopy within a short interval , but there is poor inter-observer agreement for the two categories . In this line, Matalka et al. developed an automated intelligent system to quantitatively assess inflammatory bowel system, which proved to be reliable and minimizes inter- and intraobserver variability . In our ROC analysis for UC-III and UC-IIa showing p53 basal positivity, the sensitivity (0.78) and negative predictive value (87.4%) were improved when the cutoff value was 46.1%. At this threshold, only 2.3% of UC-IIa, but 61.5% of UC-IIb crypts were classified as UC-III.
A major goal in screening for definitive dysplasia is minimizing the false negative rate; therefore, we identified a threshold of p53 basal positivity (i.e., > 40%) at which 17.2% of UC-IIa crypts were interpreted as UC-III, and only 13.6% of UC-III crypts were missed from definitive dysplasia. This indicates moderate-to-high sensitivity (86.4%) and specificity (82.8%). These values are consistent with the finding that 20% of UC-IIa crypts and 92% of UC-III crypts harbored p53 mutations . When p53 basal positivity is above this threshold, even if the biopsy diagnosis is morphologically indefinite for early-stage neoplasia in H&E stained biopsy specimens, we recommend genetic analysis for p53 or appropriate treatment, such as endoscopic or surgical resection.
Our present findings suggest that using computer-assisted cytometrical analysis of p53 basal positivity with an optimal threshold (standardization) represents an alternative to visual estimation as an accurate tool for detecting UC-associated early-stage neoplasia. The choice of an appropriate therapeutic strategy may be informed by using p53 basal positivity in biopsy samples in UC patients.
The authors thank Dr. Bun-ei Iizuka (Institute of Gastroenterology, Tokyo Women’s Medical University) for supplying clinical data. We thank Chiaki Matsuyama, Ayako Shimizu, Takako Ono, Midori Katayama, Sizuka Kidate, and Atsuko Kikuchi (Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine) for their technical assistance and secretarial assistance. This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (#24590429 to Hiroyuki Mitomi and #23590410 to Takahiro Fujimori).
- Itzkowitz SH, Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004, 126: 1634-1648. 10.1053/j.gastro.2004.03.025.PubMedView ArticleGoogle Scholar
- Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): american college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2004, 99: 1371-1385. 10.1111/j.1572-0241.2004.40036.x.PubMedView ArticleGoogle Scholar
- Fujii S, Katsumata D, Fujimori T: Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia. Digestion. 2008, 77 (Suppl 1): 2-12.PubMedView ArticleGoogle Scholar
- Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardley JH: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983, 14: 931-968. 10.1016/S0046-8177(83)80175-0.PubMedView ArticleGoogle Scholar
- Eaden J, Abrams K, McKay H, Denley H, Mayberry J: Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001, 194: 152-157. 10.1002/path.876.PubMedView ArticleGoogle Scholar
- Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994, 107: 369-378.PubMedGoogle Scholar
- Noffsinger AE, Belli JM, Miller MA, Fenoglio-Preiser CM: A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. Histopathology. 2001, 39: 482-492. 10.1046/j.1365-2559.2001.01274.x.PubMedView ArticleGoogle Scholar
- Fujii S, Fujimori T, Chiba T: Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res. 2003, 22: 107-115.PubMedGoogle Scholar
- Harpaz N, Peck AL, Yin J, Fiel I, Hontanosas M, Tong TR, Laurin JN, Abraham JM, Greenwald BD, Meltzer SJ: p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol. 1994, 25: 1069-1074. 10.1016/0046-8177(94)90067-1.PubMedView ArticleGoogle Scholar
- Taylor HW, Boyle M, Smith SC, Bustin S, Williams NS: Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg. 1993, 80: 442-444. 10.1002/bjs.1800800411.PubMedView ArticleGoogle Scholar
- Sato A, MacHinami R: p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int. 1999, 49: 858-868. 10.1046/j.1440-1827.1999.00965.x.PubMedView ArticleGoogle Scholar
- Shigaki K, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R, Takenoshita S: Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. Hum Pathol. 2013, 44: 2393-2399. 10.1016/j.humpath.2013.06.008.PubMedView ArticleGoogle Scholar
- Wong NA, Mayer NJ, MacKell S, Gilmour HM, Harrison DJ: Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology. 2000, 37: 108-114. 10.1046/j.1365-2559.2000.00934.x.PubMedView ArticleGoogle Scholar
- Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD: p53 and β catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol. 1999, 23: 963-969. 10.1097/00000478-199908000-00015.PubMedView ArticleGoogle Scholar
- Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS: Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012, 36: 1761-1770. 10.1097/PAS.0b013e318263207c.PubMedView ArticleGoogle Scholar
- Fujimori Y, Fujimori T, Imura J, Sugai T, Yao T, Wada R, Ajioka Y, Ohkura Y: An assessment of the diagnostic criteria for sessile serrated adenoma/polyps: SSA/Ps using image processing software analysis for Ki67 immunohistochemistry. Diagn Pathol. 2012, 7: 59-PubMedPubMed CentralGoogle Scholar
- Konishi F, Wakasa H, Kino I, Watanabe H, Nagura H, Muto T: Histological classification of the neoplastic changes arising in ulcerative colitis: a new proposal in Japan. J Gastroenterol. 1995, 30 (Suppl VIII): 20-24.PubMedGoogle Scholar
- Matalka II, Al-Omari FA, Salama RM, Mohtaseb AH: A novel approach for quantitative assessment of mucosal damage in inflammatory bowel disease. Diagn Pathol. 2013, 8: 156-10.1186/1746-1596-8-156.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.